Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Cramer likes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and highlighted the company’s catalysts, including its ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals (NASDAQ ... quarter -- and a significant portion of the programs in its research and development (R&D) pipeline. Its steady work over the year delivered a large market ...

Vertex Pharmaceuticals (VRTX) announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

Investors should also take note of any recent adjustments to analyst estimates for Vertex Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change ...

Vertex Pharmaceuticals' suzetrigine is an investigational ... has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people ...